Jennifer Soung

Dermatology

1125 E 17th St
Santa Ana, CA 92701

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults.

Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults.

Journal: JAMA dermatology

Published: September 02, 2026

Correction to: Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.

Correction to: Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.

Journal: American journal of clinical dermatology

Published: July 28, 2026

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

Journal: Dermatology and therapy

Published: June 24, 2026

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

Journal: American journal of clinical dermatology

Published: June 18, 2026

Ease of Use of the Lebrikizumab Prefilled Pen for Individuals with Atopic Dermatitis.

Ease of Use of the Lebrikizumab Prefilled Pen for Individuals with Atopic Dermatitis.

Journal: Patient preference and adherence

Published: April 07, 2026

Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.

Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.

Journal: Journal of the American Academy of Dermatology

Published: February 24, 2026

Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD randomized controlled trial.

Improvements in clinical and patient-reported outcomes and durability of response with the targeted oral peptide icotrokinra in adolescents with moderate-to-severe plaque psoriasis: One-year results from the ICONIC-LEAD randomized controlled trial.

Journal: Journal of the American Academy of Dermatology

Published: February 20, 2026

Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.

Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.

Journal: American journal of clinical dermatology

Published: February 20, 2026

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial.

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial.

Journal: Dermatology and therapy

Published: February 13, 2026

Real-World Evidence of Brodalumab Effectiveness for the Treatment of Psoriasis.

Real-World Evidence of Brodalumab Effectiveness for the Treatment of Psoriasis.

Journal: Journal of drugs in dermatology : JDD

Published: February 05, 2026

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

Journal: The British journal of dermatology

Published: January 30, 2026

Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.

Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents.

Journal: The New England journal of medicine

Published: November 05, 2025

Showing 1-12 of 42

Last Updated: 09/26/2026